# Molecular Adequacy of Image-Guided Rebiopsies for M Nonâ€“Small Cell Lung Cancer: A Single-Center Experie

Journal of Thoracic Oncology

13, 63-72

DOI: 10.1016/j.jtho.2017.09.1958

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Feasibility of reâ€biopsy and EGFR mutation analysis in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 856-864. | 0.8 | 21 |
| 2 | Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center. PLoS ONE, 2019, 14, e0221065. | 1.1 | 11 |
| 3 | Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Annals of Oncology, 2019, 30, 963-969. | 0.6 | 30 |
| 4 | Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer, 2019, 130, 87-92. | 0.9 | 39 |
| 5 | Nondiagnostic Percutaneous Transthoracic Needle Biopsy of Lung Lesions: A Multicenter Study of Malignancy Risk. Radiology, 2019, 290, 814-823. | 3.6 | 42 |
| 6 | Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. Journal of the American Society of Cytopathology, 2020, 9, 332-345. | 0.2 | 21 |
| 7 | Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. Korean Journal of Radiology, 2021, 22, 2082. | 1.5 | 6 |
| 8 | The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. OncoTargets and Therapy, 2020, Volume 13, 13425-13435. | 1.0 | 5 |
| 9 | 2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology. Korean Journal of Radiology, 2021, 22, 263. | 1.5 | 31 |
| 10 | Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guidelines from the College of American Pathologists (CAP). Journal of Molecular Pathology, 2021, 2, 23-28. | 0.5 | 0 |
| 11 | Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. Journal of Clinical Pathology, 2022, 75, 612-619. | 1.0 | 11 |
| 12 | Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. Journal of Cancer Research and Clinical Oncology, 2021, , 1. | 1.2 | 3 |
| 13 | Adequacy of samples obtained via percutaneous core-needle rebiopsy for EGFR T790M molecular analysis in patients with non-small cell lung cancer following acquired resistance to first-line therapy: a systematic review and meta-analysis. Cancer Treatment and Research Communications, 2021, 29, 100470. | 0.7 | 3 |
| 14 | The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small-cell lung cancer. Translational Cancer Research, 2021, 10, 0-0. | 0.4 | 2 |
| 15 | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer. Cancer Research and Treatment, 2019, 51, 1488-1499. | 1.3 | 6 |
| 16 | Correlation of transrenal DNA with non-small-cell lung cancer in noninvasive disease monitoring. Biomarkers in Medicine, 2021, 15, 1553-1562. | 0.6 | 1 |
| 17 | Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine. Current Oncology Reports, 2022, 24, 1035-1044. | 1.8 | 2 |
| 18 | Practical consideration for successful sequential tumor biopsies in first-in-human trials. Investigational New Drugs, 2022, 40, 841-849. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Liquid biopsy assay for pulmonary adenocarcinoma using supernatants from <scp>coreâ€needle</scp> biopsy specimens. Thoracic Cancer, 2022, , . | 0.8 | 3 |